SGLT2 Diabetes Drugs Associated with Doubled Risk of Dangerous Levels of Acid in Blood

Medical Drug Safety

A cohort study of 140,352 diabetics showed that sodium-glucose cotransporter 2 (SGLT2 inhibitors) diabetes drugs were associated with approximately twice the risk of diabetic ketoacidosis as were dipeptidyl peptidase-4 (DPP4 inhibitors) diabetes drugs according to a recent letter to the New England Journal of Medicine. SGLT2 inhibitors are a class of prescription medicines that are…

Read More

Invokana Litigation Alleging Kidney and Ketoacidosis Injuries Could Become an MDL (Multidistrict Litigation)

Medical Drug Safety

Last week, a motion was filed requesting multidistrict litigation (MDL) for lawsuits of individuals with kidney damage or diabetic ketoacidosis from taking the prescription, Invokana. Invokana (canagliflozin) is an oral prescription used to help lower blood glucose in patients with type 2 diabetes. Multidistrict litigation is a special procedure in which federal civil (noncriminal) cases from around the…

Read More